{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:03:06Z","timestamp":1792098186778,"version":"4.4.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9,1]]},"abstract":"<jats:title>Learning Objectives<\/jats:title>\n               <jats:p>After completing this course, the reader will be able to: Describe the benefits of bisphosphonate treatment in patients with bone metastases from breast cancer.Summarize the association between decreases in elevated urinary NTX levels during the first 3 months of zoledronic acid treatment and clinical outcomes such as survival, time to disease progression, and time to first SRE.Describe the association, if any, between bone marker levels and an impending SRE.<\/jats:p>\n               <jats:p>Access and take the CME test online and receive 1 AMA PRA Category 1 Credit\u2122 at CME.TheOncologist.com<\/jats:p>","DOI":"10.1634\/theoncologist.12-9-1035","type":"journal-article","created":{"date-parts":[[2007,10,3]],"date-time":"2007-10-03T21:19:30Z","timestamp":1191446370000},"page":"1035-1043","source":"Crossref","is-referenced-by-count":85,"title":["Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity"],"prefix":"10.1093","volume":"12","author":[{"given":"Allan","family":"Lipton","sequence":"first","affiliation":[{"name":"a Milton S. Hershey Medical Center, Penn State Cancer Institute, Hershey, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[{"name":"b University of Waterloo, Department of Statistics and Actuarial Science, Waterloo, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Major","sequence":"additional","affiliation":[{"name":"c Juravinski Cancer Centre, Hamilton,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[{"name":"d Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Coleman","sequence":"additional","affiliation":[{"name":"e University of Sheffield, Weston Park Hospital, Cancer Research Centre, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,9,1]]},"reference":[{"key":"2021122208424493800_R1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2407-6-179","article-title":"Clinical management of women with metastatic breast cancer: A descriptive study according to age group","volume":"6","author":"Manders","year":"2006","journal-title":"BMC Cancer"},{"key":"2021122208424493800_R2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"2021122208424493800_R3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med Care"},{"key":"2021122208424493800_R4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/ctrv.2000.0212","article-title":"Bone markers in the management of metastatic bone disease","volume":"27","author":"Lipton","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"2021122208424493800_R5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122208424493800_R6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1023\/A:1008238422151","article-title":"Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease","volume":"8","author":"Vinholes","year":"1997","journal-title":"Ann Oncol"},{"key":"2021122208424493800_R7","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","article-title":"Markers of bone resorption in patients treated with pamidronate","volume":"34","author":"Lipton","year":"1998","journal-title":"Eur J Cancer"},{"key":"2021122208424493800_R8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2021122208424493800_R9","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021122208424493800_R10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003474.pub2","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122208424493800_R11","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"2021122208424493800_R12","first-page":"1904","article-title":"The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation","volume":"82","author":"Rosen","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122208424493800_R13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"2021122208424493800_R14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/0471722146","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2000","edition":"Second Edition"},{"key":"2021122208424493800_R15","first-page":"1","volume-title":"Statistical Models and Methods for Lifetime Data","author":"Lawless","year":"2003","edition":"Second Edition"},{"key":"2021122208424493800_R16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/9781118032985","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"2002","edition":"Second Edition"},{"key":"2021122208424493800_R17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"2021122208424493800_R18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/clinchem\/41.10.1489","article-title":"Biochemical markers of bone turnover in patients with metastatic bone disease","volume":"41","author":"Demers","year":"1995","journal-title":"Clin Chem"},{"key":"2021122208424493800_R19","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"2021122208424493800_R20","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"suppl 4","key":"2021122208424493800_R21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: Preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"The Oncologist"},{"issue":"suppl 3","key":"2021122208424493800_R22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2005.09.002","article-title":"Anti-tumour activity of zoledronic acid","volume":"31","author":"Clezardin","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"2021122208424493800_R23","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122208424493800_R24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2021122208424493800_R25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1385\/MO:22:2:195","article-title":"Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline","volume":"22","author":"Mystakidou","year":"2005","journal-title":"Med Oncol"},{"key":"2021122208424493800_R26","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"issue":"suppl 1","key":"2021122208424493800_R27","first-page":"S260","article-title":"Fractures negatively affect survival in patients with bone metastases from breast cancer","volume":"94","author":"Hei","year":"2005","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.12-9-1035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.12-9-1035","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/9\/1035\/41835529\/oncolo_12_9_1035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/9\/1035\/41835529\/oncolo_12_9_1035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T15:05:17Z","timestamp":1640185517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/12\/9\/1035\/6398802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,1]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2007,9,1]]},"published-print":{"date-parts":[[2007,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.12-9-1035","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,9,1]]},"published":{"date-parts":[[2007,9,1]]}}}